aap Implantate’s preliminary FY17 results show an encouraging 20% y-o-y growth in trauma revenues, with the strongest performance coming from the North American distribution business. Management has guided to continued revenue growth and reducing EBITDA losses in FY18. Delivery on key partnerships and the commercialisation of the silver-coating technology are the main stepping points to eventual profitability. The near-term goal for aap is to start the human clinical trial for the silve
21 Feb 2018
Preliminary FY17 sales in line with guidance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Preliminary FY17 sales in line with guidance
aap Implantate AG (AAQ1:ETR) | 0 0 5.5% | Mkt Cap: 50.5m
- Published:
21 Feb 2018 -
Author:
Dr Andy Smith -
Pages:
2
aap Implantate’s preliminary FY17 results show an encouraging 20% y-o-y growth in trauma revenues, with the strongest performance coming from the North American distribution business. Management has guided to continued revenue growth and reducing EBITDA losses in FY18. Delivery on key partnerships and the commercialisation of the silver-coating technology are the main stepping points to eventual profitability. The near-term goal for aap is to start the human clinical trial for the silve